Datopotamab Deruxtecan (Dato-DXd) in Advanced Triple-Negative Breast Cancer (TNBC): Updated Results From the Phase 1 TROPION-PanTumor01 Study

被引：15
|
作者：
Bardia, Aditya
Krop, Ian
Meric-Bernstam, Funda
Tolcher, Anthony W.
Mukohara, Toru
Lisberg, Aaron
Shimizu, Toshio
Hamilton, Erika
Spira, Alexander I.
Papadopoulos, Kyriakos P.
Greenberg, Jonathan
Gu, Wen
Kobayashi, Fumiaki
Zebger-Gong, Hong
Kawasaki, Yui
Wong, Rie
Kogawa, Takahiro
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P6-10-03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-10-03
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): Results of the randomized phase 3 study TROPIONLung01
    Atmaca, A.
    Ahn, M.
    Lisberg, A.
    Paz-Ares, L.
    Cornelissen, R.
    Girard, N.
    Pons-Tostivint, E.
    Baz, D.
    Sugawara, S.
    Cobo, M.
    Perol, M.
    Mascaux, C.
    Poddubskaya, E.
    Kitazono, S.
    Hayashi, H.
    Sands, J.
    Hall, R.
    Zhang, Y.
    Zebger-Gong, H.
    Okamoto, I
    Schumann, C.
    PNEUMOLOGIE, 2024, 78 : S99 - S99
  • [32] Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial
    Bardia, A.
    Jhaveri, K.
    Im, S. A.
    Simon, S. Pernas
    De laurentiis, M.
    Wang, S.
    Martinez, N.
    Borges, G. Santos
    Cescon, D. W.
    Hattori, M.
    Lu, Y. S.
    Hamilton, E. P.
    Zhang, Q. Y.
    Tsurutani, J.
    Kalinsky, K.
    Xu, L.
    Denduluri, N.
    Rugo, H. S.
    Xu, B.
    Pistilli, B.
    ANNALS OF ONCOLOGY, 2023, 34 : S1264 - S1265
  • [33] Datopotamab deruxtecan (Dato-DXd), a TROP2 antibody-drug conjugate, vs investigators' choice of chemotherapy in previouslytreated, inoperable or metastatic HR+/HER2-breast cancer: TROPION-Breast01
    Bardia, Aditya
    Kalinsky, Kevin
    Tsurutani, Junji
    Hamilton, Erika
    Sohn, Joo Hyuk
    Park, Kyong Hwa
    Park, Yeon Hee
    Im, Seock-Ah
    Lee, Keun Seok
    Dastur, Daisy
    Haddad, Vincent
    Khan, Sabrina
    Xu, Binghe
    Pistilli, Barbara
    Rugo, Hope
    CANCER RESEARCH, 2023, 83 (05)
  • [34] A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).
    Yoh, Kiyotaka
    Goto, Yasushi
    Thomas, Michael
    Spira, Alexander I.
    Sands, Jacob
    Johnson, Melissa Lynne
    Greenberg, Jonathan
    Petrich, Adam Matthew
    Guevara, Ferdinand M.
    Phillips, Penny
    Alexandris, Ekaterine
    Gu, Jessie
    Zhang, Yong
    Shuster, Dale Edward
    Lisberg, Aaron Elliott
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] A phase 1b, multicenter, open-label study of valemetostat in combination with DXd antibody drug conjugates (ADCs), trastuzumab deruxtecan (T-DXd) or datopotamab deruxtecan (Dato-DXd), in patients with solid tumors
    Sands, Jacob
    Tolaney, Sara M.
    Ueno, Naoto Tada
    Spira, Alexander I.
    Yamamoto, Noboru
    Janjigian, Yelena Y.
    Naito, Yoichi
    Damodaran, Senthil
    Meric-Bernstam, Funda
    Modi, Shanu
    Enzinger, Peter C.
    Mohapatra, Avani Shah
    Iko, Yuka
    He, Siwen
    Nakajima, Keiko
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] TROPION-Breast04: A phase 3 study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab vs the standard of care in treatment-naive early-stage triple negative or HR-low/HER2-breast cancer
    McArthur, Heather
    Tolaney, Sara
    Loibl, Sibylle
    Dent, Rebecca
    Schmid, Peter
    Asselah, Jamil
    Song, Erwei
    Niikura, Naoki
    CANCER RESEARCH, 2024, 84 (09)
  • [37] TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC)
    Goto, Yasushi
    Su, Wu-Chou
    Levy, Benjamin Philip
    Rixe, Olivier
    Yang, Tsung-Ying
    Tolcher, Anthony W.
    Lou, Yanyan
    Zenke, Yoshitaka
    Savvides, Panos
    Felip, Enriqueta
    Domine, Manuel
    Leventakos, Konstantinos
    Provencio, Mariano
    Horiike, Atsushi
    Pan, Edward
    Lin, Daisy
    Gu, Jessie
    Basak, Priyanka
    Chisamore, Michael Jon
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2-breast cancer
    Mcarthur, Heather L.
    Tolaney, Sara M.
    Dent, Rebecca
    Schmid, Peter
    Asselah, Jamil
    Liu, Qiang
    Meisel, Jane Lowe
    Niikura, Naoki
    Park, Yeon Hee
    Werutsky, Gustavo
    Bianchini, Giampaolo
    Andersen, Jay C.
    Kozarski, Robert
    Rokutanda, Nana
    Pistilli, Barbara
    Loibl, Sibylle
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2025, 17
  • [39] Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05
    Lisberg, Aaron
    Ahn, Myung-Ju
    Kitazono, Satoru
    Cho, Byoung Chul
    Blumenschein, George R.
    Shum, Elaine
    Pons-Tostivint, Elvire
    Goto, Yasushi
    Yoh, Kiyotaka
    Paz-Ares, Luis G.
    Heist, Rebecca Suk
    Baas, Paul
    Planchard, David
    Perol, Maurice
    Felip, Enriqueta
    Su, Wu-Chou
    Zebger-Gong, Hong
    Lan, Lan
    Liu, Chelsea
    Sands, Jacob
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [40] Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes (PROs) from the TROPION-Breast01 study
    Pernas, Sonia
    Im, Seock-Ah
    Hattori, Masaya
    Xu, Binghe
    Wang, Shusen
    Lu, Yen-Shen
    Borges, Giuliano
    Tsurutani, Junji
    Jhaveri, Komal L.
    Zhang, Qingyuan
    De laurentiis, Michelino
    Martinez-Janez, Noelia
    Hamilton, Erika P.
    Rugo, Hope S.
    Kalinsky, Kevin
    Tolaney, Sara M.
    Shi, Lei
    Khan, Sabrina Sharmin
    Zhu, Yanyan
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345